License

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Eye, Food and Drug Administration, Research, Food, Security (finance), Woman, End-user license agreement, American Academy, Patient, Phenylephrine, Presbyopia, FDA, Agonist, Tropicamide, License, Conference, Night vision, OCUP, Met, SPA, Mydriasis, Congress, Diabetic retinopathy, LPC, Pharmaceutical industry, Medical imaging, Cryptocurrency, Viatris, Ophthalmology

FARMINGTON HILLS, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Named as CEO; Conference Call Scheduled for December 5th, 2023, at 10 AM ET
    FARMINGTON HILLS, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • On August 10, 2023, Ocuphire entered into a common share purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”).
  • Third Quarter ended September 30, 2023, Financial Highlights
    As of September 30, 2023, Ocuphire had cash and cash equivalents of approximately $42.4 million.
  • For further details on Ocuphire’s financial results, refer to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, to be filed with the Securities and Exchange Commission.

Cielo Announces Closing of Asset Purchase Transaction with Expander Energy Inc. and Results of Shareholder Meeting

Retrieved on: 
Friday, November 10, 2023
Sale, Acquisition, Engineering, CFO, End-user license agreement, Asset purchase agreement, License, Creosote, FOR, News, EPA, Transaction, Person, Transport, Interest, Canadian Pacific Railway, TSX Venture Exchange, Biomass, Culture, TCD, Protected area, Partnership, Research, CMC, Security (finance), Management, Oil, Lease, Project, Cielo, Expander, Operation, Loan

CALGARY, Alberta, Nov. 10, 2023 (GLOBE NEWSWIRE) --  Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a waste-to-fuel environmental technology company, is pleased to announce that it has closed the asset purchase transaction (the “Transaction”) with Expander Energy Inc. (“Expander”) announced on September 20, 2023.

Key Points: 
  • CALGARY, Alberta, Nov. 10, 2023 (GLOBE NEWSWIRE) --  Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a waste-to-fuel environmental technology company, is pleased to announce that it has closed the asset purchase transaction (the “Transaction”) with Expander Energy Inc. (“Expander”) announced on September 20, 2023.
  • Pursuant to an asset purchase agreement dated September 15, 2023, as amended and restated on November 8, 2023 (the “Asset Purchase Agreement”) between Cielo and Expander, Cielo has acquired assets and liabilities of Expander to operate the EBTL™ and BGTL™ technologies business being acquired from Expander (the “Acquired Business”).
  • Ryan Jackson, CEO of Cielo, commented, “The completion of this agreement is a significant achievement for Cielo and Expander shareholders.
  • Cielo and Expander have agreed to make certain amendments to the Asset Purchase Agreement, including the removal of Cielo’s financing obligations.

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Business development, Food, Carcinoma, End-user license agreement, Patient, FDA, Hart–Scott–Rodino Antitrust Improvements Act, DLL3, License, Novartis, Pharmaceutical industry

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement (License Agreement) with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 ( NCT05680922 ).1 The License Agreement grants Novartis the exclusive worldwide rights to develop, manufacture and commercialize these cell therapies, and Novartis may apply its T-Charge™ platform to their manufacture.

Key Points: 
  • Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement (License Agreement) with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 ( NCT05680922 ).1 The License Agreement grants Novartis the exclusive worldwide rights to develop, manufacture and commercialize these cell therapies, and Novartis may apply its T-Charge™ platform to their manufacture.
  • Legend Biotech is initiating clinical development of LB2102 for the treatment of extensive stage small cell lung cancer and large cell neuroendocrine carcinoma after the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application in 2022.
  • “We believe LB2102 has an innovative CAR design and armor mechanism that increases its anti-tumor activity.
  • Under the terms of the License Agreement, Legend Biotech will receive a $100 million upfront payment and will be eligible to receive up to $1.01 billion in clinical, regulatory and commercial milestone payments and tiered royalties.

Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)

Retrieved on: 
Thursday, December 14, 2023
Pancreatic cancer, QD, Policy, Therapy, Contributor License Agreement, NMPA, EMA, Patient, TGCT, BTD, U.S. FDA, FDA, FTD, License, Tenosynovial giant cell tumor, ORR, Fast Track, Merck Group, Pharmaceutical industry, Hong Kong

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients that are not amenable to surgery.

Key Points: 
  • SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients that are not amenable to surgery.
  • Previously, pimicotinib was granted the breakthrough therapy designation ("BTD") by the U.S. FDA for TGCT in January, 2023.
  • Fast Track is a policy designed to facilitate the development and expedite the review of drugs in order to treat serious conditions and fulfill unmet medical needs.
  • Pimicotinib is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor, independently developed by Abbisko Therapeutics.

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

Retrieved on: 
Wednesday, December 13, 2023
Licensing factor, Johns Hopkins University, FGF, HUVEC, Inhibitor, JHU, Itraconazole, Basal-cell carcinoma, Therapy, National Cancer Institute, VDAC1, INTI, Literature, Cell proliferation, Patient, BCC, EGF, Angiogenesis inhibitor, Prostate cancer, Endothelium, AMPK, VEGF, Neoplasm, System, License, Blood, Enzyme inhibitor, Cancer, ATP, Lung cancer, Growth, API, Metastasis, Invention, RNA, Patent, Pharmaceutical industry, Vaccine

TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors". Angiogenesis Inhibitors, as described by the National Cancer Institute, are unique cancer fighting agents as they block the growth of blood vessels that support tumor growth rather than blocking the growth of the tumor cells themselves. Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.

Key Points: 
  • TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors".
  • Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.
  • Inhibitor believes the License is a mutually beneficial agreement, yielding a modest annual royalty rate with milestone payments typical to such a license.
  • A total of 13 new 'surgically eligible' lesions across 8 of the 38 patients developed over the duration of the study.

Aker Carbon Capture awarded Process Design Package for Uniper's Grain power station in the UK, to potentially capture over 2 million tonnes of CO2 per year

Retrieved on: 
Wednesday, December 13, 2023
Carbon, CCS, CCGT, FEED, Isle, FID, Engineering, UK Government Web Archive, Engineering, procurement, and construction, CO2, Government, Combined cycle power plant, License, Process, Uniper, Isle of Grain, Electricity, PDP, GBP, EPC, Coal, Renewable energy

OSLO, Norway, Dec. 13, 2023 /PRNewswire/ -- Uniper has awarded Aker Carbon Capture a Process Design Package (PDP) to deliver design studies for a proposed post combustion carbon capture plant at their Grain power station in the Southeast of England, on the Isle of Grain, in Kent.

Key Points: 
  • OSLO, Norway, Dec. 13, 2023 /PRNewswire/ -- Uniper has awarded Aker Carbon Capture a Process Design Package (PDP) to deliver design studies for a proposed post combustion carbon capture plant at their Grain power station in the Southeast of England, on the Isle of Grain, in Kent.
  • Uniper's Grain Carbon Capture project is a proposal to retrofit post combustion carbon capture technology on up to all three of the existing Combined Cycle Gas Turbine (CCGT) units at the power plant, with the potential to capture over 2 million tonnes of CO2 per year.
  • This highly optimized design will make use of Aker Carbon Capture's best in class intellectual property, process design expertise and project execution experience.
  • The Grain Carbon Capture project will contribute towards Uniper's ambitious strategy to make our European power generation 80% carbon neutral by 2030.

Aker Carbon Capture awarded Process Design Package for Uniper's Grain power station in the UK, to potentially capture over 2 million tonnes of CO2 per year

Retrieved on: 
Wednesday, December 13, 2023
Carbon, CCS, CCGT, FEED, Isle, FID, Engineering, UK Government Web Archive, Engineering, procurement, and construction, CO2, Government, Combined cycle power plant, License, Process, Uniper, Isle of Grain, Electricity, PDP, GBP, EPC, Coal, Renewable energy

OSLO, Norway, Dec. 13, 2023 /PRNewswire/ -- Uniper has awarded Aker Carbon Capture a Process Design Package (PDP) to deliver design studies for a proposed post combustion carbon capture plant at their Grain power station in the Southeast of England, on the Isle of Grain, in Kent.

Key Points: 
  • OSLO, Norway, Dec. 13, 2023 /PRNewswire/ -- Uniper has awarded Aker Carbon Capture a Process Design Package (PDP) to deliver design studies for a proposed post combustion carbon capture plant at their Grain power station in the Southeast of England, on the Isle of Grain, in Kent.
  • Uniper's Grain Carbon Capture project is a proposal to retrofit post combustion carbon capture technology on up to all three of the existing Combined Cycle Gas Turbine (CCGT) units at the power plant, with the potential to capture over 2 million tonnes of CO2 per year.
  • This highly optimized design will make use of Aker Carbon Capture's best in class intellectual property, process design expertise and project execution experience.
  • The Grain Carbon Capture project will contribute towards Uniper's ambitious strategy to make our European power generation 80% carbon neutral by 2030.

Lightwave Logic Issues Shareholder Letter and Provides Corporate Update

Retrieved on: 
Monday, December 4, 2023
Cloud, Sale, Invention, Photonic integrated circuit, SEM, Engineering, All Access Europe, PIC, 1310, End-user license agreement, Die (integrated circuit), Polymer, Learning, History, Modulation, Intellectual property, Artificial intelligence, Optica, LightWave 3D, Patent, License, Conference, Internet, Growth, Programmable interrupt controller, AI, Silicon, Letter, EO, Travel, Logic, Internet service provider, 3D printing, Television, Management

ENGLEWOOD, Colo., Dec. 4, 2023 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to transmit data at higher speeds with less power in a small form factor, today issued a letter to shareholders from its Chairman and Chief Executive Officer, Dr. Michael Lebby.

Key Points: 
  • 2023 has been a transformational year for Lightwave Logic, underscored by the first commercial material supply and license agreement for our electro-optic polymer materials and ongoing efforts to build on this commercialization momentum.
  • Throughout the year we focused on industry awareness efforts, evangelizing the benefits of our platform at leading industry events globally.
  • Per the terms of the non-exclusive material supply and license agreement, the licensee shall pay Lightwave Logic a running royalty with a minimum royalty paid on an annual basis over the term of the License Agreement.
  • I will be hosting a fireside chat today with the hosts of the Benzinga All-Access show to discuss this shareholder letter, recent milestone achievements and potential near-term catalysts.

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

Retrieved on: 
Monday, December 4, 2023
Therapy, Contributor License Agreement, Patient, Science, License, Partnership, Health care, Pharmaceutical industry, Merck, Hong Kong

SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany.

Key Points: 
  • SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany.
  • Abbisko Therapeutics has also granted Merck an exclusive option for global commercial rights of pimicotinib, subject to the terms and conditions as agreed between the parties (the "Global Commercialization Option").
  • Pursuant to the License Agreement, Abbisko Therapeutics will receive a one-time, non-refundable down payment of US$ 70 million.
  • In the event that Merck exercises the Global Commercialization Option, Merck will pay Abbisko Therapeutics an additional option exercise fee.

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

Retrieved on: 
Tuesday, November 28, 2023
Dai, PRISM, PPI, Lilly, Patient, License, System Technology-i Co, Ltd, Eli Lilly and Company, Drug discovery, Pharmaceutical industry, Collaboration

PRISM BioLab receives upfront payments and up to $660 million in total milestones, plus royalties on net sales.

Key Points: 
  • PRISM BioLab receives upfront payments and up to $660 million in total milestones, plus royalties on net sales.
  • TOKYO, Nov. 28, 2023 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company ("Lilly").
  • Under the agreement, PRISM and Lilly will collaborate to discover small molecule inhibitors of a PPI target selected by Lilly utilizing PRISM's proprietary PepMetics® technology.
  • "We are very excited to enter into this collaboration with Lilly as we apply our technology to expand the field of drug discovery into a novel approach to drug the PPI targets," said Dai Takehara, President and Chief Executive Officer of PRISM Biolab.